DE2253086C3 - Preserving solutions for infusion and for storage of tissues and tissue parts - Google Patents

Preserving solutions for infusion and for storage of tissues and tissue parts

Info

Publication number
DE2253086C3
DE2253086C3 DE19722253086 DE2253086A DE2253086C3 DE 2253086 C3 DE2253086 C3 DE 2253086C3 DE 19722253086 DE19722253086 DE 19722253086 DE 2253086 A DE2253086 A DE 2253086A DE 2253086 C3 DE2253086 C3 DE 2253086C3
Authority
DE
Germany
Prior art keywords
tissues
storage
infusion
solutions
tissue parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE19722253086
Other languages
German (de)
Other versions
DE2253086B2 (en
DE2253086A1 (en
Inventor
Martin Prof. Dr. 1000 Berlin Wenzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19722253086 priority Critical patent/DE2253086C3/en
Publication of DE2253086A1 publication Critical patent/DE2253086A1/en
Publication of DE2253086B2 publication Critical patent/DE2253086B2/en
Application granted granted Critical
Publication of DE2253086C3 publication Critical patent/DE2253086C3/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Description

Es ist bekannt, Lösungen für Körperinfusionen mit geeigneten Ionen und Nährstoffen zu versehen. So können derartige Lösungen im einfacheren Fall einen Gehalt von 0,9% NaCl besitzen; sie können aber auch eine Vielzahl von Ionen, Glukose, Serum-Eiweiß sowie weitere Blutbestandteile gelöst enthalten. Ähnliche Lösungen verwendet man zur in-vitro-Behandlung von überlebendem Gewebe, z. B. für Zellkulturen oder zur Konservierung von vitalen Organen. In sämtlichen Fällen dient als Lösungsmittel für die zu lösenden Stoffe normales Wasser, manchmal mit geringen Anteilen von Glycerin.It is known to provide solutions for body infusions with suitable ions and nutrients. So In the simpler case, such solutions can contain 0.9% NaCl; but they can too contain a large number of dissolved ions, glucose, serum protein and other blood components. Similar Solutions are used for the in vitro treatment of surviving tissue, e.g. B. for cell cultures or for Preservation of vital organs. In all cases serves as a solvent for the substances to be dissolved normal water, sometimes with small amounts of glycerine.

Es wurde nun gefunden, daß derartige Lösungen oder Medien biologische Objekte wie Zellen, Organe und den Gesamtorganismus gegen Schädigungen besser konservieren, wenn dem üblichen Lösungsmittel Wasser (H2O) ein Anteil von 2—99,9% schweren Wassers (D2O) zugesetzt wird. Als besonders vorteilhafter Konzentrationsbereich uat sich ein Schwerwasser-Anteil von 7—25% erwiesen. Die Stabilisierung biologischer Systeme nimmt bis zu einem Schwerwasser-Anteil von 10—15% besonders stark zu. Eine weitere Erhöhung der Schwerwasserkonzentration führt zwar zu einer weiteren Erhöhung der biologischen Stabilisierung, der relative Effekt ist aber geringer.It has now been found that such solutions or media preserve biological objects such as cells, organs and the entire organism better against damage if the usual solvent water (H 2 O) contains 2-99.9% heavy water (D 2 O). is added. A heavy water content of 7-25% has proven to be a particularly advantageous concentration range. The stabilization of biological systems increases particularly strongly up to a heavy water content of 10-15%. A further increase in the heavy water concentration leads to a further increase in biological stabilization, but the relative effect is less.

Manchmal wird man zweckmäßigerweise den Schwerwasser-Anteil im primären Medium so hoch bemessen, daß die Schwerwasserkonzentration nach Verdünnung durch den Wasseranteil im Gewebe wieder 7—25% beträgtSometimes the proportion of heavy water in the primary medium is expediently so high measured that the heavy water concentration after dilution by the water content in the tissue again 7-25%

Die erfindungsgemäß D2O-haltigen Lösungen erlauben die Konservierung der nativen biologischen Eigenschaften von Zellen und Organen über einen längeren Zeitraum als im entsprechenden H2O-Medium. Eine spezielle Anwendung ist das Durchströmen von Organen, die zu Transplantationszwecken konserviert werden sollen. Dabei kann mit der erfindungsgemäßen Lösung, die noch zusätzlich Blutanteile gelöst oder in Suspension enthalten kann, den Organen zusätzlich Sauerstoff zugeführt werden.The D2O-containing solutions according to the invention allow the native biological solutions to be preserved Properties of cells and organs over a longer period of time than in the corresponding H2O medium. A special application is the perfusion of organs that have been preserved for transplantation purposes should be. Here, with the solution according to the invention, which also dissolved or in Can contain suspension, the organs are additionally supplied with oxygen.

Eine weitere Anwendung ergibt sich bei der Konservierung von Seren, Blutkonserven und Enzymen und ähnlichem biologischem Material, das im Laufe der Zeit oder durch zu hohe oder zu tiefe Temperaturen denaturiert wird. Auch hierbei ist die Effektivität einer D2O-Konzentration im Bereich von 7—25% besonders ausgeprägtAnother application is the preservation of serums, blood products and enzymes and similar biological material that changes over time or from temperatures that are too high or too low is denatured. Here, too, the effectiveness of a D2O concentration in the range of 7-25% is special pronounced

Die stabilisierenden Effekte von schwerem Wasser bei Erythrocyten beim Erwärmen bzw. beim Gefrieren und bei osmotischer Schädigung gehen aus folgenden Kurven hervor.The stabilizing effects of heavy water on erythrocytes when heated or when frozen and in the case of osmotic damage can be seen from the following curves.

6060

2020th

20 40 U K20 40 U K

Änderung des Schutzeffektes mit der D2O-Konzentration bei Erythrocyten:Change in the protective effect with the D 2 O concentration in erythrocytes:

Obere Kurve: Hämolyse durch Hyperthermie 55° C, 40 min, 5%ige Zellsuspension mit 9 g/l NaCl,Upper curve: hemolysis by hyperthermia 55 ° C, 40 min, 5% cell suspension with 9 g / l NaCl,

Mittlere Kurve: Hämolyse hypoosmotische Salz-Konzentration (3,8 g/l NaCl), 5%ige Zellsuspension 20° C, 20 min,Middle curve: hemolysis hypoosmotic salt concentration (3.8 g / l NaCl), 5% Cell suspension 20 ° C, 20 min,

Untere Kurve: Hämolyse durch Gefrieren -196° C, 12 h (Abkühlung -4,3°/min), 5%ige Zellsuspension
55 Lower curve: hemolysis by freezing -196 ° C, 12 h (cooling -4.3 ° / min), 5% cell suspension
55

Aus der Kurve ist ersichtlich, daß bei den drei geprüften Schädigungsarten der Schutzeffekt nicht linear mit der Zunahme der D2O-Konzentration ansteigt, sondern daß bereits bei einer Konzentration von ca. 20% D2O 60—75% der maximalen Schutzwirkung erreicht wird.The curve shows that with the three types of damage tested, the protective effect does not increase linearly with the increase in the D2O concentration, but that 60-75% of the maximum protective effect is achieved at a concentration of approx. 20% D 2 O.

Claims (2)

Patentansprüche:Patent claims: 1. Konservierende Lösungen zu Infusionszwecken oder zur Aufbewahrung von Organen und Geweben sowie Gewebeteilen, Eiweißen oder Enzymen, dadurch gekennzeichnet, daß sie als Lösungsmittel schweres Wasser enthalten.1. Preserving solutions for infusion purposes or for the storage of organs and tissues as well as tissue parts, proteins or enzymes, characterized in that they are as Solvents contain heavy water. 2. Lösungen gemäß Anspruch 1, dadurch gekennzeichnet, daß sie einen Schwerwasseranteil von 7—25% enthalten. 2. Solutions according to claim 1, characterized in that they contain a heavy water content of 7-25%.
DE19722253086 1972-10-25 1972-10-25 Preserving solutions for infusion and for storage of tissues and tissue parts Expired DE2253086C3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19722253086 DE2253086C3 (en) 1972-10-25 1972-10-25 Preserving solutions for infusion and for storage of tissues and tissue parts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19722253086 DE2253086C3 (en) 1972-10-25 1972-10-25 Preserving solutions for infusion and for storage of tissues and tissue parts

Publications (3)

Publication Number Publication Date
DE2253086A1 DE2253086A1 (en) 1974-05-09
DE2253086B2 DE2253086B2 (en) 1978-06-15
DE2253086C3 true DE2253086C3 (en) 1979-02-15

Family

ID=5860372

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19722253086 Expired DE2253086C3 (en) 1972-10-25 1972-10-25 Preserving solutions for infusion and for storage of tissues and tissue parts

Country Status (1)

Country Link
DE (1) DE2253086C3 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662185B2 (en) 1999-12-30 2010-02-16 Osteotech, Inc. Intervertebral implants
US7726002B2 (en) 2001-12-05 2010-06-01 Osteotech, Inc. Processes for making spinal intervertebral implant, interconnections for such implant
US7780708B2 (en) 2000-10-20 2010-08-24 Osteotech, Inc. Implant retaining device
US8202539B2 (en) 2007-10-19 2012-06-19 Warsaw Orthopedic, Inc. Demineralized bone matrix compositions and methods
US8328876B2 (en) 2003-12-31 2012-12-11 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US8333985B2 (en) 2004-01-27 2012-12-18 Warsaw Orthopedic, Inc. Non-glycerol stabilized bone graft
US8357384B2 (en) 2007-06-15 2013-01-22 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US8372157B2 (en) 2007-02-12 2013-02-12 Warsaw Orthopedic, Inc. Joint revision implant
US8642061B2 (en) 2007-06-15 2014-02-04 Warsaw Orthopedic, Inc. Method of treating bone tissue
US8734525B2 (en) 2003-12-31 2014-05-27 Warsaw Orthopedic, Inc. Osteoinductive demineralized cancellous bone
US8911759B2 (en) 2005-11-01 2014-12-16 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US9011537B2 (en) 2009-02-12 2015-04-21 Warsaw Orthopedic, Inc. Delivery system cartridge
US9333082B2 (en) 2007-07-10 2016-05-10 Warsaw Orthopedic, Inc. Delivery system attachment
US9554920B2 (en) 2007-06-15 2017-01-31 Warsaw Orthopedic, Inc. Bone matrix compositions having nanoscale textured surfaces

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2738299A (en) * 1998-03-10 1999-09-27 Imperial College Of Science, Technology And Medicine Solution

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662185B2 (en) 1999-12-30 2010-02-16 Osteotech, Inc. Intervertebral implants
US8672980B2 (en) 2000-10-20 2014-03-18 Warsaw Orthopedic, Inc. Implant retaining device
US7780708B2 (en) 2000-10-20 2010-08-24 Osteotech, Inc. Implant retaining device
US7726002B2 (en) 2001-12-05 2010-06-01 Osteotech, Inc. Processes for making spinal intervertebral implant, interconnections for such implant
US9034358B2 (en) 2003-12-31 2015-05-19 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US9415136B2 (en) 2003-12-31 2016-08-16 Warsaw Orthopedic, Inc. Osteoinductive demineralized cancellous bone
US8328876B2 (en) 2003-12-31 2012-12-11 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US8734525B2 (en) 2003-12-31 2014-05-27 Warsaw Orthopedic, Inc. Osteoinductive demineralized cancellous bone
US8333985B2 (en) 2004-01-27 2012-12-18 Warsaw Orthopedic, Inc. Non-glycerol stabilized bone graft
US8911759B2 (en) 2005-11-01 2014-12-16 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US8992965B2 (en) 2005-11-01 2015-03-31 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US8372157B2 (en) 2007-02-12 2013-02-12 Warsaw Orthopedic, Inc. Joint revision implant
US8642061B2 (en) 2007-06-15 2014-02-04 Warsaw Orthopedic, Inc. Method of treating bone tissue
US8357384B2 (en) 2007-06-15 2013-01-22 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US9554920B2 (en) 2007-06-15 2017-01-31 Warsaw Orthopedic, Inc. Bone matrix compositions having nanoscale textured surfaces
US9333082B2 (en) 2007-07-10 2016-05-10 Warsaw Orthopedic, Inc. Delivery system attachment
US9358113B2 (en) 2007-07-10 2016-06-07 Warsaw Orthopedic, Inc. Delivery system
US9492278B2 (en) 2007-07-10 2016-11-15 Warsaw Orthopedic, Inc. Delivery system
US8435566B2 (en) 2007-10-19 2013-05-07 Warsaw Orthopedic, Inc. Demineralized bone matrix compositions and methods
US8202539B2 (en) 2007-10-19 2012-06-19 Warsaw Orthopedic, Inc. Demineralized bone matrix compositions and methods
US9011537B2 (en) 2009-02-12 2015-04-21 Warsaw Orthopedic, Inc. Delivery system cartridge
US9101475B2 (en) 2009-02-12 2015-08-11 Warsaw Orthopedic, Inc. Segmented delivery system
US9220598B2 (en) 2009-02-12 2015-12-29 Warsaw Orthopedic, Inc. Delivery systems, tools, and methods of use

Also Published As

Publication number Publication date
DE2253086B2 (en) 1978-06-15
DE2253086A1 (en) 1974-05-09

Similar Documents

Publication Publication Date Title
DE2253086C3 (en) Preserving solutions for infusion and for storage of tissues and tissue parts
Caldwell Studies on the internal pH of large muscle and nerve fibres
Gasic et al. Removal of sialic acid from the cell coat in tumor cells and vascular endothellum, and its effects on metastasis
CH624579A5 (en)
DE2161820A1 (en) Process for the storage of biological substances
DE2735453B2 (en) Method for storing blood
DE2655801A1 (en) METHOD FOR PRODUCING A MASS OF LOADED CELLS SUSPENDED IN A PHYSIOLOGICAL SOLUTION
DE2656746A1 (en) METHOD FOR PRODUCING A MASS OF LOADED CELLS SUSPENDED IN A PHYSIOLOGICAL SOLUTION
CH641046A5 (en) METHOD FOR PRODUCING PERMANENT UROKINASE AGENTS.
DE4331711C2 (en) Solution for perfusion, preservation and re-perfusion of organs
DE2258519C3 (en) Process for obtaining a cosmetological product
CH657502A5 (en) METHOD FOR PRODUCING FLEXIBLE, SUSTAINABLY MADE NON-PRESERVED AND PRESERVED BIOLOGICAL MATERIALS.
EP0012272B1 (en) Protecting solution for heart and kidneys and process for its manufacture
Gayton et al. The location of chloride in single striated muscle fibers of the giant barnacle
Pelikán et al. The toxic effects of tri-n-butyltin compounds on white mice
Zerbst-Boroffka Organische Säurereste als wichtigste Anionen im Blut von Hirudo medicinalis
EP0898889B1 (en) Washing solution for blood cells
Ponder The permeability of human red cells to cations after treatment with resorcinol, n-butyl alcohol, and similar lysins
Marwitz et al. Elektronenmikroskopische Untersuchungen über das Vorkommen mykoplasmaähnlicher Organismen in triebsuchtkranken Apfelbäumen.
DE2020329A1 (en) Process for the production of sparsely cross-linked, crystal-clear, swellable hydrogels that can be used as glass body substitutes
DE710410C (en) Process for increasing the coagulability of animal blood
YABUKI Received for publication Aug., 24. 1927.
DE1296307B (en) Process for the preparation of a vaccine against Brucella abortus infections
Amon Methodische Untersuchungen zum histochemischen Nachweis von Elektrolyten
DE932146C (en) Process for the production of stabilized, aqueous hyaluronidase solutions

Legal Events

Date Code Title Description
OGA New person/name/address of the applicant
C3 Grant after two publication steps (3rd publication)
8339 Ceased/non-payment of the annual fee